Barclays
CYTK icon

Barclays’s Cytokinetics CYTK Stock Holding History

Barclays’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.52M Buy
83,800
+48,800
+139% +$3.1M ﹤0.01% 1758
2025
Q4 		$2.22M Buy
+35,000
New +$2.18M ﹤0.01% 2861
2025
Q3 		– Sell
-200
Closed -$6.61K – 5534
2025
Q2 		$6.61K Buy
+200
New +$6.96K ﹤0.01% 4951
2024
Q4 		– Sell
-10,000
Closed -$528K – 5313
2024
Q3 		$528K Buy
+10,000
New +$557K ﹤0.01% 3744
2024
Q2 		– Sell
-188,200
Closed -$13.2M – 4955
2024
Q1 		$13.2M Buy
+188,200
New +$14.6M ﹤0.01% 1217

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Barclays's CYTK Position: Q1 2026 in Review

Barclays reduced its Cytokinetics (CYTK) stake by 77% in Q1 2026, selling an estimated $16.8M and leaving 79,159 shares worth $5.22M. The position accounts for ﹤0.01% of the portfolio, ranked #1793.

Barclays first reported a position in CYTK in Q3 2013 and has held it in 51 quarters since. The position peaked at $53.4M in Q1 2024. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Barclays held 79,159 shares of Cytokinetics worth $5.22M as of Q1 2026.
  • Barclays sold 264,299 Cytokinetics shares in Q1 2026, an estimated $16.8M.
  • Cytokinetics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1793 holding.
  • Barclays first reported a position in Cytokinetics in Q3 2013 and has held it in 51 quarters since.
  • Barclays's Cytokinetics position peaked at $53.4M in Q1 2024.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.